- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04107935
Telemedicine for Reach, Education, Access and Treatment-ongoing (TREAT-ON)
December 14, 2023 updated by: Linda Siminerio, University of Pittsburgh
Diabetes (DM) management requires health care providers to provide patients with the appropriate amount of time, education and support that are necessary for quality care.
Unfortunately, this is often impeded by limited access to resources, particularly in rural communities where DM rates are high and providers are scarce.
Therefore, study investigators propose addressing these issues by implementing a model of care that includes diabetes educator (DE)-led planned visits with a real-time videoconferencing telemedicine program for ongoing patient support to improve DM outcomes.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Health care systems need to seek ways through quality improvement, care coordination, and workforce capacity to support quality care.
It has been proposed that new models of care coupled with technology are needed.
DM provides an ideal model for testing new approaches as the number of people with DM continues to rise, with an inverse shortage of health providers available to meet their needs.
Most patients with Type 2 DM (T2DM) are seen in primary care (PC) where providers report barriers to comprehensive care that include limited time, educational resources, added workload and feeling ill-equipped to counsel patients on behavior change.
Efforts to restructure PC are underway, like DE-led planned management visits, reported to improve healthy behaviors and outcomes in patients at high risk.
DEs are well suited to support the skills, decision making, self-care behaviors, problem solving and active collaboration with the care team that serve as the foundation for diabetes self-management education and key to an effective planned visit.
DEs supporting care and self-management education in PC have been shown to improve access and outcomes.
For patients to sustain a lifetime of behavior to effectively self-manage, continued support to sustain the ongoing skills, knowledge, and behaviors required to manage their condition is needed.
Given the need for enduring support and scarcity of providers, particularly in underserved rural areas, efforts to understand how best to re-design practice to involve DEs in PC and utilize technology to enable and scale engagement in self-management and ongoing support must be considered.
The purpose of this application is to evaluate the deployment of Telemedicine for Reach, Education, Access, Treatment and Ongoing Support (TREAT-ON), a DE-driven, PC-based telemedicine model that relies on PC practice redesign to afford access to real-time ongoing support.
Investigators hypothesize that the TREAT-ON model will help individuals identified as being high risk in an underserved rural community to achieve and sustain improvements in clinical, psychosocial and behavioral outcomes, and aim to demonstrate the model's viability in terms of feasibility and acceptability to inform future testing of TREAT-ON.
Study Type
Interventional
Enrollment (Actual)
43
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Intervention group: UPMC Health Plan patient-members who are 18-75y, have diagnosis of type 2 diabetes, are considered "high risk" (HbA1c >9%), receiving care at participating Federally Qualified Health Centers, and willing and able to participate in a technology-supported intervention.
- Control group: The control group will be selected from individuals who have already participated in the UPMC Health Plan's Diabetes High Risk Initiative.
Exclusion Criteria:
- Non UPMC Health Plan patients
- Not enrolled in the UPMC Health Plan Diabetes High Risk Initiative
- Less than 18 or greater than 75 years of age
- Unwilling/unable to participate in the telemedicine diabetes education program
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
|
TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform.
Like the usual care intervention, "high risk" patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services.
Participants will complete an initial face-to-face visit with the DE to assess needs and develop a self-management treatment plan and goals.
Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes.
Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes.
|
Other: Usual Care
|
A retrospective control group will be formed from individuals who have previously participated in a program called the "Diabetes High Risk Initiative."
In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care.
Patients typically participate in one face-to-face visit with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Glycemic Control
Time Frame: Change every 3 months for 12 months.
|
Average change in HbA1c every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only one result reported per arm.
|
Change every 3 months for 12 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Diabetes Self-care Behavior [Diet] Across 3 Month Intervals for 12 Months.
Time Frame: Change every 3 months for 12 months total.
|
Summary of Diabetes Self-care Activities Measure was used to evaluate self-care with questions about number of days in a week that the participant reports self-care behaviors.
Individual items are scored 0 (minimum) to 7 (maximum) for number of days the behavior is performed.
The total possible score ranges from 0 to 7. The higher the score for dietary behavior, the better.
For this study, average change in scores from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only one result reported per arm.
|
Change every 3 months for 12 months total.
|
Change From Baseline in Diabetes Distress Across 3 Month Intervals for 12 Months
Time Frame: Change every three months for 12 months total
|
Diabetes distress was evaluated with the 17-item Diabetes Distress Scale, which assesses four dimensions of distress - emotional, regimen, interpersonal and physician (Polonsky et al, 2005), and has shown a consistent pattern of relationships with HbA1c, diabetes self-efficacy, diet and physical activity in multiple samples of patients with T2DM (Fisher et al, 2012).
Individual items are scored from 1 to 6; total scores are the average of all individual item scores; higher scores indicate greater distress (represents worse outcome).
Possible score range 1 to 6.
For this study, average change in scores every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only 1 result reported per arm.
|
Change every three months for 12 months total
|
Change From Baseline in Diabetes Empowerment Across 3 Month Intervals for 12 Months
Time Frame: Change every 3 months for 12 months total
|
Empowerment was measured using the 8-item Diabetes Empowerment Scale-Short Form, which measures an individual's perceived ability to manage psychosocial aspects of diabetes, assess dissatisfaction and readiness to change self-management plans and set and achieve diabetes goals (Anderson et al, 2000; Anderson et al, 2003).
Possible scores are 1 to 5 for each item, summed for a possible total score of 8 to 40.
Higher scores indicate greater empowerment (better outcome).
For this study, average change in scores every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only 1 result reported per arm.
|
Change every 3 months for 12 months total
|
Intervention Acceptability
Time Frame: 12 months
|
Telemedicine Usability Questionnaire was used to assess telehealth usefulness, ease of use and learnability, interface quality, patient-clinician interaction, reliability, satisfaction and future use and included additional items specific to this study.
Individual items are scored on a scale from one to five, with one being strongly disagree to five being strongly agree.
Scores are averaged for a possible score range of one to five.
The higher the score infers the better the usability of the telehealth service.
|
12 months
|
Change From Baseline in Medication Adherence Across 3 Month Intervals for 12 Months
Time Frame: Change every 3 months for 12 months total
|
Medication adherence was assessed with the 8-item Morisky Medication Adherence Scale (MMAS-8).
The scales includes 8 items.
Scores can range from 0 to 8; the higher the score, the more adherent the respondent is considered.
For this study, average change in scores every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only 1 result reported per arm.
|
Change every 3 months for 12 months total
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Linda Siminerio, RN, PhD, CDE, University of Pittsburgh
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 4, 2020
Primary Completion (Actual)
August 4, 2022
Study Completion (Actual)
December 9, 2022
Study Registration Dates
First Submitted
September 25, 2019
First Submitted That Met QC Criteria
September 25, 2019
First Posted (Actual)
September 27, 2019
Study Record Updates
Last Update Posted (Actual)
December 18, 2023
Last Update Submitted That Met QC Criteria
December 14, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- STUDY19080005
- 1R34DK123370-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
After completion of the study, study investigators will prepare a consolidated dataset with all data collected as part of this study (e.g., clinical, behavioral, psychosocial, and satisfaction).
All potentially identifying information will be removed.
In addition, study investigators will prepare a Manual of Operations with a detailed description of the diabetes self-management and support intervention, the technology delivery system and a full description of the TREAT-ON model for dissemination.
IPD Sharing Time Frame
Study protocol and data set - After publication.
ICF - After data collection is completed.
IPD Sharing Access Criteria
Study protocol and data set - other researchers will have to request access.
ICF will be added to clinicaltrials.gov
protocol
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
Clinical Trials on TREAT-ON
-
University of Alabama at BirminghamUS Department of Veterans Affairs; Agency for Healthcare Research and Quality...RecruitingUrinary IncontinenceUnited States
-
Johns Hopkins UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedHIV Infections | AlcoholismUnited States
-
Indiana UniversityCompletedTraumatic Brain Injury | AlexithymiaUnited States
-
Columbia UniversityCompleted
-
University of EdinburghNot yet recruiting
-
Yale UniversityNational Institute of Mental Health (NIMH)Not yet recruitingED-TREAT (Early Detection and Treatment to Reduce Events With Agitation Tool) Compared to Usual CarePsychomotor Agitation | Behavioral DisorderUnited States
-
Region of Southern DenmarkUniversity of Southern Denmark; JaschaFondenNot yet recruitingOther Specified Feeding or Eating Disorder | Eating Disorder NosDenmark
-
UPECLIN HC FM Botucatu UnespCompleted
-
Jinling Hospital, ChinaCompleted
-
NHS Greater Glasgow and ClydeUniversity of GlasgowRecruiting